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; Zudin Puthucheary, MBBS 3, 4 ; Jakirty Rawal, MBBS 3 ; Constantine J. Karvellas Objective: To evaluate the role of hepatocellular and extrahepatic apoptosis during the evolution of acetaminophen-induced acute liver failure. Design and Setting: A prospective observational study in two tertiary liver transplant units. Patients: Eighty-eight patients with acetaminophen-induced acute liver failure were recruited. Control groups included patients with nonacetaminophen-induced acute liver failure (n = 13), nonhepatic multiple organ failure (n = 28), chronic liver disease (n = 19), and healthy controls (n = 11). Measurements: Total and caspase-cleaved cytokeratin-18 (M65 and M30) measured at admission and sequentially on days 3, 7, and 10 following admission. Levels were also determined from hepatic vein, portal vein, and systemic arterial blood in seven patients undergoing transplantation. Protein arrays of liver homogenates from patients with acetaminophen-induced acute liver failure were assessed for apoptosis-associated proteins, and histological assessment of liver tissue was performed.
Main Results: Admission M30 levels were significantly elevated in acetaminophen-induced acute liver failure and non-acetaminophen induced acute liver failure patients compared with multiple organ failure, chronic liver disease, and healthy controls. Admission M30 levels correlated with outcome with area under receiver operating characteristic of 0.755 (0.639-0.885, p < 0.001). Peak levels in patients with acute liver failure were seen at admission A cute liver failure (ALF) is a rare but devastating clinical syndrome caused by the sudden loss of function and viability of a critical mass of hepatocytes. Liver cell death leads directly to the jaundice, coagulopathy, and encephalopathy that are the clinical hallmarks of this condition which carries a transplant-free survival of less than 50% (1) .
Acetaminophen overdose is the commonest cause of ALF in the United States and United Kingdom accounting for 42% and 57% of cases, respectively (2, 3) . Controversy exists regarding whether hepatocellular death occurs as a result of necrosis, apoptosis, or a combination of both processes (4) . Experimental models of acute liver injury indicate that the majority of hepatocytes die via necrosis, as the sudden and comprehensive loss of mitochondrial function does not permit cells to execute the adenosine triphosphate (ATP)-dependent process of apoptosis (5, 6) . There is, however, evidence that when cellular ATP levels are preserved, hepatocytes can undergo apoptosis, with the induction of cellular caspases (7) (8) (9) . Studies in human acetaminophen-induced ALF (AALF) have demonstrated the presence of caspase-cleaved cytokeratin-18 (CK-18) fragments in patient's sera suggesting cellular apoptosis. However, a recent study failed to demonstrate active caspase-3 in patients with AALF and thus concluded apoptosis was not a significant phenomenon in this condition (10) .
Following the initial toxic insult, the course of acetaminophen poisoning is characterized by activation of innate immune responses that propagate acute liver injury. This is characterized by elevations in protoxicant mediators and recruitment and activation of immune effectors (e.g., natural killer/natural killer T cell cells, neutrophils) that perpetuate liver injury via a number of mechanisms, including tumor necrosis factor-α and Fasmediated hepatocyte apoptosis (11) . These responses are likely to be major determinants in not only the progression but also the eventual outcome in human AALF. The resolution phase of AALF is difficult to replicate in animal models, yet increasing our understanding of the pathophysiologic processes involved during the evolution of ALF, from acute liver injury to multiple organ dysfunction is of pivotal importance (12) .
Circulating concentrations of apoptosis and necrosis markers based on caspase-cleaved and intact CK-18 have been proposed as biomarkers of disease severity and may fulfill an important role in risk stratifying patients with AALF (13) (14) (15) . However, as published studies show conflicting results regarding the prognostic utility of these markers, the temporal changes in CK-18-based markers and the contribution of nonhepatic epithelial tissues require further evaluation.
This study aims to assess the role of apoptosis during the clinical course of AALF. We report the results of serum markers of apoptosis and necrosis at admission to hospital in a large cohort of patients with AALF and present longitudinal data on the progression of these markers through the first 10 hospital days, including the assessment of hepatic apoptosis at the time of liver transplantation.
MATERIALS AND METHODS

Patient Selection and Sample Collection
The study was approved by a local ethics committee and patients or their nominee gave written informed consent within 24 hours of presentation to Kings College Hospital and the E Garner King General Systems Intensive Care Unit, University of Alberta, Canada.
AALF Cohort. Sixty-two nonconsecutive patients presenting to King's College Hospital with a clinical history of excess acetaminophen ingestion, deranged liver function tests, and contemporaneous or subsequent development of ALF (as defined by a jaundice to encephalopathy time of < 28 d) (16) were initially recruited. Clinical and demographic data, including age, sex, biochemistry, arterial blood gas, physiology, and Acute Physiology and Chronic Health Evaluation (APACHE) score, were collected from patients at the time of blood sampling. Patient outcomes were recorded as spontaneous survival, death or liver transplantation, with poor outcome defined as death or transplantation. Blood samples were collected in lithium heparin tubes from patients within 48 hours of admission. Blood was centrifuged at 13,000 rpm for 10 minutes at 4°C for separation of plasma. Plasma aliquots were stored at -80°C pending analysis. Fifteen patients with AALF were also recruited from the E Garner King General Systems Intensive Care Unit, University of Alberta, Edmonton, Canada.
Control Cohorts. Pathologic control cohorts were recruited from patients at Kings College Hospital with blood sampling and plasma isolation performed as above. Control groups included 13 patients with ALF of a nonacetaminophen etiology (viral, n = 3; seronegative, n = 5; nonacetaminophen druginduced liver injury, n = 5), 19 patients with stable chronic liver disease (CLD) recruited from outpatient clinics, 11 healthy controls (HC), and 28 intubated and ventilated general intensive care patients with multiple organ failure (MOF).
Sequential Levels
In a subcohort of 26 patients with AALF (15 from Edmonton and 11 from the United Kingdom), plasma samples were drawn on days 1, 3, 7, and 10 following admission to delineate the time course of total and cleaved caspases following the initial liver injury.
Regional Levels
In seven AALF patients undergoing liver transplantation, blood was collected intraoperatively from the portal vein (PV), hepatic vein (HV), and a systemic artery (the renal artery) prior to PV clamping. Blood samples were immediately dispensed into lithium-heparin tubes and centrifuged and plasma stored as above.
Tissue Collection
Liver explant tissue was collected from six patients with AALF at the time of transplantation. Fresh tissue blocks were dissected immediately following removal of the liver and flash frozen in liquid nitrogen before storing at -80°C until required. Control liver tissue was obtained from donor liver in which consent for research was in place.
Total and Cleaved CK-18 Quantification
Plasma levels of uncleaved CK-18 (M65) and caspase-cleaved CK-18 (M30) were quantified with commercially available enzyme-linked immunosorbent assays (Peviva AB, Bromma, Sweden), previously validated in clinical trials and used according to manufacturer's instructions as described elsewhere (17) .
Apoptosis Proteome Array
AALF and control liver tissues were lysed by disruption in lysis buffer. Protein content was determined using modified Lowry protein determination assay according to Schacterle and Pollack (18), which is based on Lowry et al (19) . Samples were diluted with phosphate-buffered saline to give a normalized final concentration of 250 µg protein per 125 µL per membrane. The focused proteome array (Proteome Profiler Array Human Apoptosis Array Kit; R&D Systems, Minneapolis, MN) was performed according to manufacturer's instructions. Membranes were exposed to an autoradiography cassette for 6 minutes. Film was scanned and analyzed in ImageJ (ImageJ, U. S. National Institutes of Health, Bethesda, MD; http://imagej. nih.gov/ij/). Following inversion and subtraction of background exposure, the integrated density of each dot was measured and averaged between duplicates.
Histology
Hematoxylin and eosin-stained liver explant tissue was examined by an expert histopathologist (A.Q.) for evidence of apoptotic bodies. Double-epitope immunohistochemistry was performed using antibodies to Ki-67 (clone MIB1, Dako, Glostrup, Denmark), Hep Par1 (clone OCH1E5, Dako, Glostrup, Denmark), and Ki67 plus CK-19 (NCL-CK19, Novocastra, Newcastle, UK). A Leica Bond max detection system (Leica Microsystems, GmbH, Wetzlar, Germany) was used with DAB and fast red chromogens.
Statistical Analysis
Data were assessed for normality using the D'Agostino-Pearson test and expressed as mean (sd) median (range) contingent on results with log transformation on nonnormally distributed data. Comparison was by one-way analysis of variance (ANOVA), with Tukey post hoc test applied for multiple comparison correction. Four time point sequential data were analyzed using repeat measures ANOVA. Paired t testing on log-transformed data was performed on measurements across organ beds. Apoptotic protein array profiling was analyzed by Student t test. The prognostic significance of apoptosis markers was assessed by receiver-operating characteristic (ROC) curve analysis using the DeLong method for ROC curve comparison and defining cutoff by Youden index. Statistical significance was defined at the 95% level. Data were analyzed in MedCalc v 12.2.1 (MedCalc software, Mariakerke, Belgium).
RESULTS
Elevation of CK-18 Fragments at Admission in AALF, NALF, and MOF
Participants from the United Kingdom and Canada were matched for age, sex, and liver and organ failure severity as shown in Table  1 . Elevated levels of caspase-cleaved and total CK-18 were demonstrated at admission blood samples in both ALF patient cohorts. The levels of caspase-cleaved (M30) CK-18 were significantly higher in AALF and NALF group than those in APACHE-matched MOF control patients and in patients with CLD and HC (p < 0.001; one-way ANOVA on log-transformed data) (Fig. 1) . Patients with MOF and no liver disease had levels of both M30 and M65 intermediate between the ALF cohort and patients with CLD or HC (p < 0.001; one-way ANOVA on log-transformed data) (Fig. 1) . Using the ratio of M30-M65 (an apoptosis index) failed to demonstrate a difference between patients with ALF and MOF. Patients with CLD showed the lowest levels of this index (p = 0.004; one-way ANOVA on log-transformed data, data not shown).
Prognostic Utility of Circulating Levels of M30 and M65
Levels of both M30 and M65 at admission correlated with poor outcome, as defined by death or transplantation. The performance of these assays as prognostic markers was assessed by ROC analysis. Admission M30 proved to have the greatest prognostic accuracy in this cohort with an AUROC of 0.755 (0.639-0.885, p < 0.001), sensitivity of 89%, and specificity of 61% with a cutoff of 2,718. The "apoptosis index" of M30/M65 (AUROC, 0.690 [0.553-0.826, p = 0.006]; sensitivity, 56%; specificity, 78%; cutoff, < 2.1) outperformed the M65 assay alone (AUROC, 0.569 [0.421-0.718, p = 0.359]; sensitivity, 86%; specificity, 42%) (p = 0.02 for comparison, DeLong method) (Fig. 2) . 
Clinical Correlates of Hepatic and Extrahepatic Organ
Temporal Changes in M30 Over the First 10 Days of Hospital Admission
The levels of total and caspasecleaved CK-18 were greatest on the first hospital day and The nonsignificant differences in lactate and HE grade may represent timing of transfer to these units and/or fluid resuscitation prior to inclusion. This may also explain the difference in M65 levels. A, M30 levels demonstrate significant group differences with levels in acetaminophen-induced acute liver failure (AALF) significantly higher than those in healthy controls (HC), chronic liver disease (CLD), or multiple organ failure (MOF) (*p < 0.05 for comparison with AALF group). M30 levels in the patients with MOF were intermediate and were significantly higher than those in the HC and CLD groups and lower than those in the patients with AALF. b, M65 levels demonstrate similar pattern of differences, with levels highest in AALF group and NALF patients, intermediate in MOF and CLD, and lowest in HC. Levels of this cell death-associated marker were significantly higher in AALF group than those in the non-liver failure control groups (*p < 0.05 for comparison with AALF group).
declined rapidly over the subsequent 10 days (p < 0.001 for comparison of day 1 with all other days). At days 7 and 10, M65 and M30 levels were still elevated in comparison with HC (p < 0.001) despite resolving liver failure.
Regional Levels of Cell Death Markers in Late-Stage AALF
To assess the regional concentrations of M30 and M65 in patients with established ALF, we measured the levels of total and cleaved CK-18 in seven patients at the time of transplantation. These demonstrated higher levels of M30 in the PV compared with the HV (geometric mean ratio, 0.82 [95% CI, 0.67-0.99]; p = 0.042, paired t test on log-transformed data) ( Fig. 3) with no gradient between HV and systemic arterial levels (geometric mean ratio, (Fig. 4) .
Protein Array and Histological Analysis of Apoptosis in Late-Stage AALF
As our data suggested that the hepatic epithelial bed might not be the primary source of total or cleaved CK-18 by the time of transplantation, we compared a broad panel of proteins associated with apoptosis and tissue repair/regeneration from the explant tissue of six patients with AALF and six controls. This suggested that catalase (p = 0.05) was higher in AALF liver tissue, and SMAC/Diablo (p = 0.05), hypoxiainducible factor 1α (p = 0.05), and cellular inhibitor of apoptosis-2 (p = 0.02) were lower in AALF than in control liver tissue (Fig. 5) . Tissue was examined histologically from six explants for AALF. Explants were characterized by evidence of centrilobular necrosis with marked inflammatory infiltrate. Regenerative activity was demonstrated by double-epitope immunohistochemistry showing co-staining of cells for the hepatocyte marker Hep Par-1 and Ki-67, a marker of cellular proliferation (Fig. 6A) . Biliary epithelial proliferation was also demonstrated by co-staining for CK-19 and Ki-67 (Fig. 6B) . A comprehensive assessment of the hepatic microenvironment in late stage AALF has recently been published by us and demonstrates evidence of resolution and regeneration (12) . There was an absence of apoptotic bodies or cellular morphology suggestive of apoptosis.
DISCUSSION
Here, we demonstrate evidence that hepatocellular apoptosis is present during the early phases of human AALF. Our data highlight that during the later stages of AALF, there is evidence of hepatic regenerative/tissue repair processes and an absence of hepatic apoptosis. The persistent elevations in circulating levels of M30 are thus likely to reflect apoptosis in nonhepatic epithelial beds, potentially as a consequence of multiple organ dysfunction. Our results demonstrate that serum markers of apoptosis and necrosis are markedly elevated at admission to hospital in patients with AALF compared with HC. As the CK-18-based assays are nonorgan specific, we included a control group of critically ill patients with matched APACHE II scores to determine whether the observed elevation in CK-18 markers was a nonspecific phenomenon. We are able to demonstrate that markers of both apoptosis and necrosis in AALF exceed those in critically ill controls, suggesting a hepatocellular origin of a significant proportion of the observed circulating CK-18. The finding of hepatocellular apoptosis in human AALF conflicts with evidence from many animal studies which suggest cell death is almost exclusively by necrosis (10, 20) . A possible explanation, proposed by Antoine et al 8) , is that animal studies are performed on fasted animals in whom ATP is depleted, therefore inhibiting the active process of apoptosis. Evidence from cell culture work and in vivo data in fed animals suggest that if ATP is maintained, hepatocyte apoptosis can be observed in acetaminophen poisoning (7, 8) . In clinical practice, the nonfasted status of patients at time of overdose and in-hospital standard care with nutritional support and phosphate supplementation may sustain hepatocellular ATP and permit the execution of apoptosis (21, 22) . Further work is necessary to evaluate the impact of phosphate supplementation on hepatocellular death in acute liver injury.
McGill et al (10) in a recent study of clinical AALF have demonstrated a lack of active caspase 3 in patient sera, which lead to the conclusion that apoptosis is not a significant mode of cell death in this condition. They commented that their "abnormal liver test" group had low acetaminophen levels as they presented to hospital late. If apoptosis is, as our results suggest, a transient and early process, it is possible that active caspase-3 with a short half-life would not be detected in late presenting patients. The apparent conflict between the active caspase-3 data and the consistent demonstration of caspase-cleaved CK-18 in human AALF merits further investigation.
The longitudinal data we present show a rapid decline in markers of both apoptosis and necrosis after admission to hospital. This suggests the initial peak represents cellular loss as a direct effect of the time-limited acetaminophen toxicity in the initiation phase, rather than an ongoing process. The magnitude of the initial apoptotic injury is a clear correlate of patient outcome following overdose as demonstrated by a strong relationship between admission M30 levels and patient outcome. In terms of biomarker utility, our findings of an association between poor outcome and elevated serum markers of apoptosis and necrosis are consistent with the results of a recently published multicenter study also analyzing a large cohort of patients with AALF (23) . Thus, between these two datasets a consensus is emerging that early elevation in serum cell death markers is predictive of poor outcome in AALF.
In the late stages of AALF, although caspase-cleaved and intact CK-18 concentrations fall, they persist in the circulation at levels exceeding those in HC. Results from regional sampling of blood in patients undergoing orthotopic liver transplant demonstrate peak levels of caspase-cleaved CK-18 in the PV, with a decrease in concentration across the liver. This suggests that at this late stage of disease, the liver is no longer an important source of cytokeratin fragments, but their origin may be epithelial tissue beds of the splanchnic system. Established AALF is characterized by activation of systemic inflammatory responses manifested through circulatory dysfunction and immune dysregulation that mirror the physiologic changes encountered during septic shock (24, 25) . Serum markers of apoptosis and necrosis are also elevated in sepsis, and in both human and animal models, it has been shown that intestinal epithelial cells are particularly vulnerable to apoptosis (26, 27) . This finding has been replicated in a number of noninfectious critical illnesses where marked intestinal apoptosis is observed despite a nongut primary source of tissue injury (28) (29) (30) . Experimental manipulation of intestinal apoptosis has been demonstrated to improve survival in animals with pneumonia and cecal ligation and puncture (31, 32) . These results suggest gut epithelial apoptosis is not a mere epiphenomenon in critical illness but may influence outcome. Further studies investigating intestinal epithelial apoptosis in established AALF are warranted to build on our observations and test the hypothesis that the gut undergoes apoptosis in AALF in a manner comparable to sepsis and other critical illnesses.
Immunohistochemical and proteomic examination of the explanted livers from patients with AALF also provides evidence that hepatocellular apoptosis does not continue in latestage disease. Histological assessment of explanted liver tissue shows no evidence of apoptosis in this late stage of liver failure but in tissue repair and regeneration processes. Results from the apoptosis protein arrays suggest that at the time of transplantation, the liver environment in AALF is enriched in catalase and contains a paucity of factors from the intrinsic mitochondrial apoptosis pathways when compared with HC. Catalase is a common cellular scavenger of hydrogen peroxide and peroxynitrite, whose overexpression has been shown to attenuate apoptosis (33) (34) (35) .
CONCLUSION
We provide evidence that significant hepatocellular apoptosis occurs in human AALF. It is an early and transient phenomenon likely to reflect the initiation/propagation phases of AALF and correlates with an adverse outcome. Later, in established AALF, there is no evidence of ongoing hepatocellular apoptosis, in fact our findings suggest resolution, with a regenerative liver microenvironment. The persistence of markers of apoptosis in the sera of patients with established AALF is likely to represent apoptosis in nonhepatic tissue, particularly the gut, as has been demonstrated in other conditions characterized by an overwhelming systemic inflammatory response. 
